share_log

China Vascular Grafts Market Size, Share & Trends Analysis Report 2021 - ResearchAndMarkets.com

China Vascular Grafts Market Size, Share & Trends Analysis Report 2021 - ResearchAndMarkets.com

2021年中國血管移植市場規模、份額和趨勢分析報告-ResearchandMarkets.com
Businesswire ·  2021/11/19 18:40

DUBLIN--(BUSINESS WIRE)--The "China Vascular Grafts Market Size, Share & Trends Analysis Report By Product, By Application (Kidney Failure, Vascular Occlusion, Coronary Artery Disease), By Raw Material, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

都柏林--(美國商業資訊)--“2021-2028年按產品、應用(腎衰竭、血管閉塞、冠狀動脈疾病)、原材料和細分市場預測劃分的中國血管移植市場規模、份額和趨勢分析報告” 已添加到 ResearchandMarkets.co 提供。


China's vascular grafts market size is expected to reach USD 172.8 million by 2028. The market is expected to expand at a CAGR of 8.6% from 2021 to 2028.

預計到2028年,中國的血管移植市場規模將達到1.728億美元。預計從2021年到2028年,該市場將以8.6%的複合年增長率增長。

The increasing prevalence of cardiovascular diseases, diabetes, and end-stage renal disease are the factors driving the market. The rise in the number of people suffering from these conditions is expected to boost the demand for these products in the coming years. In addition, the development of novel technologies, such as tissue-engineered materials, is expected to boost overall revenue over the forecast period. The COVD-19 pandemic has negatively impacted the country's growth due to the increasing focus on COVID-19 treatment and recommended deferrals of elective medical procedures in the country.

心血管疾病、糖尿病和終末期腎臟疾病患病率的上升是推動市場的因素。預計患有這些疾病的人數的增加將在未來幾年內提振對這些產品的需求。此外,組織工程材料等新技術的開發預計將在預測期內增加總收入。由於人們越來越關注 COVID-19 治療,並建議該國推遲選擇性醫療程序,COVD-19 疫情對該國的增長產生了負面影響。

In 2020, the endovascular stent-grafts product segment held the largest revenue share. The growth in the adoption of minimally invasive endovascular procedures due to their benefits such as short hospital stays low mortality rate, and perioperative morbidity, driving the segment growth. On the other hand, the peripheral vascular grafts segment is anticipated to be the fastest-growing segment during the forecast period owing to the increasing number of patients suffering from peripheral artery disease in China.

2020年,血管內支架移植產品板塊的收入份額最大。由於微創血管內手術的好處,例如住院時間短,死亡率低,圍手術期發病率,越來越多地採用微創血管內手術,推動了該細分市場的增長。另一方面,由於中國患有外周動脈疾病的患者人數不斷增加,預計外周血管移植領域將成爲預測期內增長最快的細分市場。

The cardiac aneurysm application segment accounted for the largest revenue share in 2020. The increasing prevalence of unruptured saccular aneurysms, affecting the flow of intracranial arteries, is expected to boost the adoption of these products over the forecast period. Abdominal Aortic Aneurysms (AAA) have a worse prognosis in men and have gained considerable attention in recent years, hence, gender-specific research about the development of novel products is expected to gain momentum over the forecast period. On the other hand, vascular occlusion application is expected to be the fastest-growing segment during the forecast period due to the increasing prevalence of vascular occlusive diseases and the easy availability of graft procedures. Technological advancements resulting in the development of novel therapies, which help to reduce the severity of acute ischemia after occlusion of PTFE grafts and thereby, minimizing the risks associated with prosthetic vascular grafts.

心臟動脈瘤應用領域佔2020年收入份額最大。未破裂的囊狀動脈瘤的患病率不斷上升,這會影響顱內動脈的流動,預計將在預測期內促進這些產品的採用。腹主動脈瘤(AAA)在男性中的預後較差,近年來引起了廣泛關注,因此,關於新產品開發的針對性別的研究預計將在預測期內獲得動力。另一方面,由於血管閉塞性疾病的患病率上升以及移植手術很容易獲得,預計血管閉塞應用將成爲預測期內增長最快的細分市場。技術進步促成了新療法的開發,這些療法有助於降低聚四氟乙烯移植物閉塞後急性缺血的嚴重程度,從而最大限度地降低與人造血管移植相關的風險。

As of 2020, the polytetrafluoroethylene raw material segment accounted for the largest revenue share. It is anticipated to witness the fastest CAGR during the forecast period. Multiple applications of polytetrafluoroethylene vascular grafts, such as replacement of diseased arteries and creation of dialysis access site, along with many players offering a variety of polytetrafluoroethylene-based products are among factors supporting overall growth. In addition, easy availability of raw material and high tensile strength and durability are also responsible for high adoption in China.

截至2020年,聚四氟乙烯原材料板塊的收入份額最大。預計將在預測期內見證最快的複合年增長率。支持整體增長的因素包括聚四氟乙烯血管移植物的多種應用,例如更換患病的動脈和建立透析通道,以及許多提供各種聚四氟乙烯基產品的參與者。此外,原材料的便捷供應以及高抗拉強度和耐久性也是中國被廣泛採用的原因。

China Vascular Grafts Market Report Highlights

中國血管移植市場報告要點

  • The market is expected to witness significant growth by 2028, owing to rising demand for minimally invasive procedures and the continuous introduction of innovative solutions.
  • The endovascular stent-grafts segment has dominated the market in 2020 due to increasing consumer preference for minimally invasive endovascular stent-grafts in China.
  • The cardiac aneurysm application segment dominated the market in 2020 due to the increasing prevalence of cardiovascular diseases in China.
  • The polytetrafluoroethylene raw material segment dominated the market in 2020 due to the rise in the number of players offering polytetrafluoroethylene vascular grafts.
  • 由於對微創手術的需求不斷增長以及創新解決方案的不斷推出,預計到2028年,該市場將實現顯著增長。
  • 由於中國消費者對微創血管內支架移植的偏好與日俱增,血管內支架移植領域在2020年佔據了主導地位。
  • 由於中國心血管疾病的患病率上升,心臟動脈瘤應用領域在2020年佔據了市場主導地位。
  • 由於提供聚四氟乙烯血管移植物的參與者數量增加,聚四氟乙烯原材料板塊在2020年佔據了市場主導地位。

Companies Mentioned

提及的公司

  • Medtronic plc
  • Terumo Corporation
  • LeMaitre Vascular, Inc.
  • C.R. Bard; W.L. Gore and Associates, Inc.
  • Cook
  • Shanghai Suokang Medical Implants Co. Ltd.
  • Getinge AB
  • 美敦力公司
  • Terumo 株式會社
  • LeMaitre Vascular, Inc.
  • C.R. Bard;W.L. Gore and Associates, Inc.
  • Cook
  • 上海碩康醫療植入物有限公司有限公司
  • Getinge AB

For more information about this report visit https://www.researchandmarkets.com/r/5gd41l

有關此報告的更多信息,請訪問 https://www.researchandmarkets.com/r/5gd41l

About ResearchAndMarkets.com

關於 ResearchandMarkets

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchandMarkets.com是全球領先的國際市場研究報告和市場數據來源。我們爲您提供有關國際和地區市場、關鍵行業、頂級公司、新產品和最新趨勢的最新數據。


Contacts
聯繫人

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

ResearchandMarket
勞拉·伍德,高級新聞經理
press@researchandmarkets.com
如需了解歐洲安全局的辦公時間,請致電 1-917-300-0470
如需美國/加拿大免費電話,請致電 1-800-526-8630
如需了解格林尼治標準時間辦公時間,請致電 +353-1-416-8900

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論